Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Probabilities of success for antibody therapeutics.

Literature DB >> 20068390

Probabilities of success for antibody therapeutics.

Janice M Reichert¹.

Abstract

Mesh：

Substances：
Antibodies, Monoclonal

Year: 2009 PMID： 20068390 PMCID： PMC2726601 DOI： 10.4161/mabs.1.4.9031

Source DB: PubMed Journal: MAbs ISSN： 1942-0862 Impact factor: 5.857

× No keyword cloud information.

6 in total

Review 1. Monoclonal antibodies in the clinic.

Authors: J M Reichert
Journal: Nat Biotechnol Date: 2001-09 Impact factor: 54.908

Review 2. Therapeutic monoclonal antibodies: trends in development and approval in the US.

Authors: Janice M Reichert
Journal: Curr Opin Mol Ther Date: 2002-04

3. Monoclonal antibodies market.

Authors: Janice Reichert; Alex Pavolu
Journal: Nat Rev Drug Discov Date: 2004-05 Impact factor: 84.694

4. Monoclonal antibody successes in the clinic.

Authors: Janice M Reichert; Clark J Rosensweig; Laura B Faden; Matthew C Dewitz
Journal: Nat Biotechnol Date: 2005-09 Impact factor: 54.908

Review 5. Monoclonal antibodies as innovative therapeutics.

Authors: Janice M Reichert
Journal: Curr Pharm Biotechnol Date: 2008-12 Impact factor: 2.837

6. Development trends for therapeutic antibody fragments.

Authors: Aaron L Nelson; Janice M Reichert
Journal: Nat Biotechnol Date: 2009-04 Impact factor: 54.908

6 in total

9 in total

Review 1. Diagnosing the decline in pharmaceutical R&D efficiency.

Authors: Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal: Nat Rev Drug Discov Date: 2012-03-01 Impact factor: 84.694

2. Swift antibodies to counter emerging viruses.

Authors: Dennis R Burton; Erica Ollmann Saphire
Journal: Proc Natl Acad Sci U S A Date: 2015-08-10 Impact factor: 11.205

3. Galactosylation variations in marketed therapeutic antibodies.

Authors: T Shantha Raju; Robert E Jordan
Journal: MAbs Date: 2012-04-26 Impact factor: 5.857

Review 4. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

Authors: Lara Marks
Journal: MAbs Date: 2012-04-26 Impact factor: 5.857

Review 5. Antibodies for biodefense.

Authors: Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal: MAbs Date: 2011-11-01 Impact factor: 5.857

Review 6. Emerging antibody combinations in oncology.

Authors: Stephen J Demarest; Kandasamy Hariharan; Jianying Dong
Journal: MAbs Date: 2011-07-01 Impact factor: 5.857

7. High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display.

Authors: Lequn Zhao; Liang Qu; Jing Zhou; Zhengda Sun; Hao Zou; Yunn-Yi Chen; James D Marks; Yu Zhou
Journal: PLoS One Date: 2014-10-29 Impact factor: 3.240

8. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.

Authors: Suzanne S Farid; Max Baron; Christos Stamatis; Wenhao Nie; Jon Coffman
Journal: MAbs Date: 2020 Jan-Dec Impact factor: 5.857

Review 9. Improving Immunotherapy Through Glycodesign.

Authors: Matthew J Buettner; Sagar R Shah; Christopher T Saeui; Ryan Ariss; Kevin J Yarema
Journal: Front Immunol Date: 2018-11-02 Impact factor: 7.561

9 in total